Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database

被引：0
|
作者：
Megan C. Roberts
Dave P. Miller
Steven Shak
Valentina I. Petkov
机构：
[1] National Cancer Institute,
[2] Genomic Health Inc.,undefined
来源：
Breast Cancer Research and Treatment | 2017年 / 163卷
关键词：
Breast cancer; Disease-specific survival; Lymph node-positive; Oncotype DX; Recurrence Score; SEER;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：303 / 310
页数：7
相关论文
共 50 条
  • [1] Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database
    Roberts, Megan C.
    Miller, Dave P.
    Shak, Steven
    Petkov, Valentina I.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (02) : 303 - 310
  • [2] Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
    Fried, Georgeta
    Moskovitz, Mor
    SPRINGERPLUS, 2014, 3 : 1 - 8
  • [3] Effect of lymph node metastasis size on breast cancer-specific and overall survival in women with node-positive breast cancer
    Brent S. Rose
    Wei Jiang
    Rinaa S. Punglia
    Breast Cancer Research and Treatment, 2015, 152 : 209 - 216
  • [4] Effect of lymph node metastasis size on breast cancer-specific and overall survival in women with node-positive breast cancer
    Rose, Brent S.
    Jiang, Wei
    Punglia, Rinaa S.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (01) : 209 - 216
  • [5] Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer
    Berdunov, Vladislav
    Millen, Steve
    Paramore, Andrew
    Hall, Peter
    Perren, Timothy
    Brown, Rebecca
    Griffin, Jane
    Reynia, Sarah
    Fryer, Nina
    Longworth, Louise
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 591 - 604
  • [6] Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptor-positive, Node-positive Breast Cancer
    Brufsky, Adam M.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (04): : 404 - 410
  • [7] Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
    Lux, Michael Patrick
    Minartz, Christof
    Mueller-Huesmann, Harald
    Sandor, Marianar Felicia
    Radeck-Knorre, Sabine
    Neubauer, Aljoscha Steffen
    BREAST CARE, 2024, 19 (01) : 27 - 33
  • [8] Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
    Varga, Zsuzsanna
    Sinn, Peter
    Fritzsche, Florian
    von Hochstetter, Arthur
    Noske, Aurelia
    Schraml, Peter
    Tausch, Christoph
    Trojan, Andreas
    Moch, Holger
    PLOS ONE, 2013, 8 (03):
  • [9] Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004–2015
    Lu Zhang
    Mei-Chin Hsieh
    Valentina Petkov
    Qingzhao Yu
    Yu-wen Chiu
    Xiao-Cheng Wu
    Breast Cancer Research and Treatment, 2020, 180 : 491 - 501
  • [10] Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015
    Zhang, Lu
    Hsieh, Mei-Chin
    Petkov, Valentina
    Yu, Qingzhao
    Chiu, Yu-wen
    Wu, Xiao-Cheng
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 491 - 501
12345